| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | https://www.hindustanbiosciences.in/ | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 3.70 Cr. | |
| Earnings per share (EPS) | -0.92 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 1.27 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 2.84 | Calculated using Price: 3.61 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.03 Cr. | 10,250,800 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society. The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology). Products The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals. Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co. In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin. |
||
Company Profile
Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.
The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).
Products
The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.
Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.
In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.
| 1 Day |
|
-0.28% |
| 1 Week |
|
-3.48% |
| 1 Month |
|
-16.05% |
| 3 Month |
|
+17.21% |
| 6 Month |
|
-13.84% |
| 1 Year |
|
+167.41% |
| 2 Year |
|
+319.77% |
| 5 Year |
|
+91.01% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -7.71 | -11.47 | -19.21 | -35.60 | -10.74 | -71.30 | 5.22 | 3.67 | -52.96 | |
| Return on Capital Employed (%) | -7.32 | -10.57 | -16.78 | -30.17 | -8.37 | -49.03 | 2.68 | 2.40 | -23.70 | |
| Return on Assets (%) | -6.96 | -10.03 | -16.51 | -30.15 | -8.42 | -47.82 | 2.37 | 1.45 | -20.83 |
| Particulars | 9 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 9 | 8 | 7 | 5 | 4 | 2 | 2 | 2 | 1 | |
| Non Curr. Liab. | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | |
| Curr. Liab. | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 10 | 10 | 8 | 6 | 6 | 4 | 6 | 6 | 3 | |
| Non Curr. Assets | 8 | 8 | 7 | 5 | 5 | 3 | 4 | 3 | 2 | |
| Curr. Assets | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | |
| Misc. Exp. not W/O | 0 | 0 | ||||||||
| Total Assets | 10 | 10 | 8 | 6 | 6 | 4 | 6 | 6 | 3 |
| Particulars | 9 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 4 | 2 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | |
| Other Income | 0 | |||||||||
| Total Income | 4 | 2 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | |
| Total Expenditure | -5 | -3 | -2 | -1 | -1 | -3 | -3 | -2 | -2 | |
| PBIDT | -1 | -1 | -1 | 0 | 0 | -2 | 0 | 0 | -1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | |||||||
| Exceptional Items | -2 | |||||||||
| PAT | -1 | -1 | -1 | -2 | 0 | -2 | 0 | 0 | -1 |
| Particulars | 9 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | |
| Cash Fr. Inv. | 0 | 0 | 0 | |||||||
| Cash Fr. Finan. | 0 | 1 | 0 | -1 | 0 | 0 | 2 | -1 | -1 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Fri, 23 Jul 2021
Voting Results For 29Th Annual General Meeting Voting results for 29th Annual General Meeting |
|
Thu, 22 Jul 2021
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Scrutinizers Report on E voting results |
|
Thu, 22 Jul 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015) Hindustan Bio Sciences Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here |
| Fri, 23 Jul 2021 |
Strongly Underperforming Benchmark index
|
Decreasing Relative Strength - Benchmark index
|
Strongly Underperforming Sectoral index
|
Decreasing Relative Strength - Sectoral index
|
Both SRS And ARS Below Zero
|
Equities
M.F.
Sectors